ENTERA BIO LTD. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ENTERA BIO LTD. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 733.70K shares.
- ENTERA BIO LTD. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 0.00 shares, a 100.00% decline from fiscal 2022.
- ENTERA BIO LTD. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 5.51K shares, a 96.90% decline from fiscal 2021.
- ENTERA BIO LTD. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 177.71K shares, a 456.14% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2024-12-31 | 733.70K shares 10-K · filed 2025-03-28 | |
| 2023-12-31 | 0.00 shares 10-K · filed 2025-03-28 | |
| 2022-12-31 | 5.51K shares 10-K · filed 2024-03-08 | |
| 2021-12-31 | 177.71K shares 10-K · filed 2023-03-31 | |
| 2020-12-31 | 31.95K shares 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |